Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp11 | Acromegaly | ECE2018

Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Escola Cristina Alvarez , Fajardo Carmen , Marazuela Monica , Carballido Fernando Cordido , Venegas Eva Maria , Velasco Pedro de Pablos , Maroto Gonzalo Piedrola , Marquez Ma del Pilar Olvera , de Paz Isabel Pavon , Carvalho Davide , Romero Carme , De la Cruz Guillermo , Bernabeu Ignacio

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...